Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02950805 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Effect of AZD5634 on Mucociliary Clearance, Safety, Tolerability and Pharmacokinetic Parameters in Patients With Cystic Fibrosis
A Phase 1 study of Pulmonary/Respiratory Diseases, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
- 3
- Study locations
NCT02950805: Completed Phase 1 study of Pulmonary/Respiratory Diseases, sponsored by AstraZeneca.
NCT02950805 is a Phase 1 study of Pulmonary/Respiratory Diseases that has completed, run by AstraZeneca. The registered enrollment target is 9 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02950805, a Phase 1 study of Pulmonary/Respiratory Diseases, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
- 3
- Study locations
Study Summary
This study will assess the effect of inhaled AZD5634 on Mucociliary clearance (MCC) in patients with Cystic fibrosis (CF) after single-dose administration.
Primary Outcome
Assessment of the average whole lung clearance between 0 and 60 minutes after administration of single inhaled dose of aerosolized radiolabelled particles (colloids) of AZD5634, (%MCC 0--60, whole) in subjects with cystic fibrosis (CF).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG AZD5634
Study Locations (3)
Alabama
- Research Site - Birmingham
Maryland
- Research Site - Baltimore
North Carolina
- Research Site - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2017-05-30 |
| Est. Completion | 2018-04-12 |
| Phase | Phase 1 |
What the finished NCT02950805 record still lists
NCT02950805 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower).
The record links to 1 condition, with Pulmonary/Respiratory Diseases appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02950805 reports a single indexed study location in Alabama, Maryland, North Carolina.
Frequently Asked Questions
What is clinical trial NCT02950805 about?
NCT02950805 is a clinical study titled "A Study to Assess the Effect of AZD5634 on Mucociliary Clearance, Safety, Tolerability and Pharmacokinetic Parameters in Patients With Cystic Fibrosis". This study will assess the effect of inhaled AZD5634 on Mucociliary clearance (MCC) in patients with Cystic fibrosis (CF) after single-dose administration.
What is the current status of trial NCT02950805?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2017-05-30. Estimated completion is 2018-04-12.
What conditions does trial NCT02950805 study?
This clinical trial studies the following conditions: Pulmonary/Respiratory Diseases.
What interventions are being tested in trial NCT02950805?
The interventions under investigation include: Placebo (DRUG), AZD5634 (DRUG).
Who is sponsoring clinical trial NCT02950805?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02950805 being conducted?
This trial has 3 study locations across Alabama, Maryland, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02950805's enrollment target sits among peer trials
9 1955th of 2000 higher than 42 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI